Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860723 | 0.84 | — | — | |
| SCHEMBL21193763 | 0.83 | CXCR2 (0.32) | CXCR2CXCR1DRD2DRD1DRD4 | |
| SCHEMBL23721841 | 0.83 | DRD2 (0.34) | DRD2DRD4DRD3 | |
| SCHEMBL4750604 | 0.77 | DRD2 (0.33) | CXCR2DRD2DRD3 | |
| SCHEMBL2255224 | 0.76 | AKR1C3 (0.32) | — | |
| SCHEMBL505204 | 0.75 | DRD2 (0.32) | CXCR2CXCR1DRD2DRD1DRD4 | |
| SCHEMBL21193631 | 0.75 | NR1H2 (0.35) | — | |
| SCHEMBL17628950 | 0.72 | DRD2 (0.33) | CXCR2CXCR1DRD2DRD1DRD4 | |
| SCHEMBL27240520 | 0.72 | DRD2 (0.33) | CXCR2CXCR1DRD2DRD1DRD4 | |
| SCHEMBL17628812 | 0.72 | DRD2 (0.33) | CXCR2CXCR1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202765-B1 | POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR | HAINAN XUANZHU PHARMA CO LTD (CN) | 2020-03-25 | — | — | EP | disclosed |
| US-10011592-B2 | Polycyclic inhibitor of anaplastic lymphoma kinase | Xuanzhu Pharma Co., Ltd. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20180086745-A9 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-03-29 | — | — | US | disclosed |
| US-20170240534-A1 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | XUANZHU PHARMA CO LTD (CN) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086745-A9 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | IKBKE, DCK, CHUK | CXCR2 4427/4885CXCR1 3611/4885DRD2 4572/4885 |
| US-10011592-B2 | Polycyclic inhibitor of anaplastic lymphoma kinase | IKBKE, DCK, CHUK | CXCR2 4427/4885CXCR1 3611/4885DRD2 4572/4885 |
| US-20170240534-A1 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | IKBKE, DCK, CHUK | CXCR2 4427/4885CXCR1 3611/4885DRD2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.